TIMEWELL
Solutions
Free ConsultationContact Us
TIMEWELL

Unleashing organizational potential with AI

ISO/IEC 27001 (ISMS) certification mark (SGS / ISMS-AC)

ISO/IEC 27001:2022 certified Certificate No. JP26/00000255 Scope: Planning, development and operation of SaaS products utilizing AI technology

Services

  • ZEROCK
  • TRAFEED (formerly ZEROCK ExCHECK)
  • TIMEWELL BASE
  • WARP
  • └ WARP 1Day
  • └ WARP NEXT Corporate
  • └ WARP BASIC
  • └ WARP ENTRE
  • └ Alumni Salon
  • └ WARP for Schools
  • AI Consulting
  • ZEROCK Buddy

Company

  • About Us
  • Team
  • Why TIMEWELL
  • News
  • Contact
  • Free Consultation

Content

  • Insights
  • Knowledge Base
  • Case Studies
  • Whitepapers
  • Events
  • Solutions
  • AI Readiness Check
  • ROI Calculator

Legal

  • Privacy Policy
  • Manual Creator Extension
  • WARP Terms of Service
  • WARP NEXT School Rules
  • Legal Notice
  • Security
  • Anti-Social Policy
  • ZEROCK Terms of Service
  • TIMEWELL BASE Terms of Service

Newsletter

Get the latest AI and DX insights delivered weekly

Your email will only be used for newsletter delivery.

© 2026 株式会社TIMEWELL All rights reserved.

Contact Us
HomeColumnsAIコンサルOpen Evidence: The AI Platform Transforming Clinical Decision-Making
AIコンサル

Open Evidence: The AI Platform Transforming Clinical Decision-Making

Published2026-02-07Ryuta Hamamoto
BusinessConsultingAIData AnalysisSustainability

Open Evidence is an AI platform built on peer-reviewed medical literature that is already used by over 100,000 US physicians.

Open Evidence: The AI Platform Transforming Clinical Decision-Making
Share

This is Hamamoto from TIMEWELL.

The AI Tool Transforming Clinical Medicine

Physicians have always faced an impossible knowledge problem: medicine advances faster than any individual can track, and the decisions they make in clinical emergencies have life-or-death consequences. Open Evidence is an AI platform built specifically to address this gap — and it is already reshaping how physicians make clinical decisions.

Open Evidence is trained exclusively on peer-reviewed medical literature. It is not a general-purpose AI chatbot. When a physician inputs a clinical question, the system searches relevant literature and extracts precisely the information needed — not just a title list, but the substantive content, organized for clinical utility. Over 100,000 physicians in the United States use it, with monthly active users exceeding 200,000.

Topics covered:

  • Real-world clinical applications and the emergency that proved Open Evidence's value
  • AI in emergency situations: capabilities and remaining challenges
  • The future of medicine: aggregating clinical wisdom
  • Summary

How Open Evidence Transforms Clinical Practice

The Emergency on the Plane

The case that most clearly illustrates Open Evidence's value involves Dr. Susan Wolver. On a commercial flight, a 63-year-old male passenger developed a rash. Dr. Wolver was on board and needed to make a rapid diagnosis and treatment decision in a severely resource-constrained environment.

The rash suggested possible chickenpox. But the patient was undergoing treatment for prostate cancer — and the cancer medication made immune suppression likely. This combination made the clinical picture genuinely difficult: in an immunosuppressed patient, chickenpox that would be mild in a healthy adult carries a risk of serious complications.

Dr. Wolver queried Open Evidence on the incubation period for the infection. The system returned CDC-sourced data confirming a typical 15-day incubation — immediately useful for assessing exposure risk relative to the patient's recent travel history.

She then provided the patient's cancer treatment context and queried the degree of immune suppression likely to result. Drawing from current medical literature and leading specialty journals, Open Evidence returned an assessment supporting a "moderate immunosuppression" classification for this patient's condition. This multi-source synthesis provided analytical depth that no single clinician's recollection could reliably match in real time.

On treatment: Open Evidence synthesized literature on antiviral selection and urgency indicators, giving Dr. Wolver a concrete treatment framework even in the absence of standard hospital resources.

A Dermatology-Neurology Case

Another example: a dermatologist treating a patient with both psoriasis and multiple sclerosis needed to understand how the psoriasis medications would interact with the neurological condition. Using Open Evidence, the physician identified potential adverse interactions and selected a safer treatment option. The cross-specialty knowledge synthesis is precisely what the platform is designed to enable.

Looking for AI training and consulting?

Learn about WARP training programs and consulting services in our materials.

Book a Free ConsultationDownload Resources

Open Evidence's Design Philosophy

Co-founder Daniel Nadler designed Open Evidence from the physician's perspective, treating doctors as users rather than as passive recipients of technology mandated by administration. The result is an app freely downloadable from the app store with no complex onboarding — physicians can start using it immediately.

The exclusive use of peer-reviewed literature as training data is a deliberate quality control decision. The reliability of clinical AI depends entirely on the quality of its sources, and Open Evidence's design eliminates the contamination risk that comes with training on unvetted web content.

Physician feedback loops are built into the development process. User evaluations and feature requests have consistently shaped the platform's evolution.

AI in Medical Emergencies: Capabilities and Challenges

The value of rapid, accurate information retrieval is proportional to the stakes of the decision — which means it is highest in exactly the situations where conventional information access is most difficult: aircraft, remote locations, rural facilities without specialist coverage.

Open Evidence addresses the core challenge that physicians face: information currency. Medical knowledge advances continuously; no individual practitioner can maintain current awareness across all domains. The platform connects to continuously updated databases, eliminating the gap between published evidence and what any given physician can recall under pressure.

The platform also handles the multi-variable nature of clinical cases. The airplane case involved an unusual combination of patient factors — age, cancer type, specific medication, travel history, resource limitations — all of which needed to be integrated simultaneously. Open Evidence's ability to synthesize across these variables reflects the complexity of real clinical medicine.

Remaining challenges are real. Information update frequency, data source transparency, usability in high-stress environments, and error-handling procedures all require ongoing attention. The development team actively incorporates user feedback to address these operational realities.

The Future of Medicine: Aggregated Clinical Wisdom

The trajectory of Open Evidence points toward something more ambitious than information retrieval. By incorporating not just published literature but the practical judgment patterns accumulated by specialists across fields — the clinical "oral tradition" of medicine that never makes it into journal articles — the platform is building toward what Nadler calls a comprehensive "clinical knowledge system."

This would give physicians access to:

  • Real-time updates on the latest evidence for any condition
  • Automated risk assessment and treatment recommendations based on current research
  • Pattern recognition across large datasets that reduces diagnostic variability and catches information gaps

The implications extend beyond individual clinical encounters. If physicians' practical knowledge can be systematically captured and aggregated, the resulting system becomes collectively smarter than any individual practitioner — and that intelligence remains accessible to the physician in a remote clinic without specialist backup.

Remote medicine: Open Evidence's evolution has significant implications for telemedicine and remote diagnosis. Specialists are unevenly distributed geographically; AI-mediated access to specialist-level knowledge could substantially reduce that disparity.

Personalized medicine: The aggregation of evidence across diseases combined with patient-specific risk factors creates the foundation for genuinely individualized treatment recommendations — not population-level guidelines, but patient-level optimization.

Nadler has said he believes Open Evidence could save over one million lives in the next decade. Given the current trajectory of medical error rates and the demonstrated value of rapid, reliable clinical decision support, that projection is not unrealistic.

Summary

Open Evidence represents a genuine inflection point in clinical medicine. Key points:

  • Over 100,000 US physicians use it actively; 200,000+ monthly active users
  • Trained exclusively on peer-reviewed medical literature — high reliability by design
  • Demonstrated value in emergency scenarios where conventional information access is unavailable
  • Cross-specialty knowledge synthesis helps physicians outside their core domain
  • Free, immediately accessible — physician-first design philosophy
  • Development roadmap points toward comprehensive aggregation of clinical wisdom
  • Potential to save millions of lives through improved clinical decision quality

The integration of AI into clinical decision-making is not a future prospect. It is happening now. Open Evidence is among the clearest demonstrations that AI can serve as a genuine clinical partner — not replacing physician judgment, but giving that judgment access to a depth of current evidence that no individual can maintain alone.

References:

  • https://www.youtube.com/watch?v=nPOZ1nA2RIw
  • https://www.youtube.com/watch?v=huR0Oa2odxA
  • https://www.openevidence.com/about

TIMEWELL AI Consulting

TIMEWELL supports business transformation in the age of AI agents.

Our services:

  • AI agent implementation: business automation using GPT-5, Claude, and Gemini
  • GEO strategy consulting: content marketing for the AI search era
  • DX and new business development: business model transformation through AI

Book a free consultation →

Related Articles

  • From Full-Time to Part-Time: A Working Mother's Perspective on Career and Childcare | TIMEWELL
  • 3 Essential Steps to Take Before Starting Paternity Leave — Even During Busy Season
  • Finding Your Own Path as a Fifth-Generation Construction Company Owner | Fujita Construction

This article was produced with the help of AI. A human verified the primary sources and edited the text before publication.

Considering AI adoption for your organization?

Our DX and data strategy experts will design the optimal AI adoption plan for your business. First consultation is free.

Book a Free Consultation
Book a Free Consultation45-minute online sessionDownload ResourcesProduct brochures & whitepapers

Share this article if you found it useful

Share

Newsletter

Get the latest AI and DX insights delivered weekly

Your email will only be used for newsletter delivery.

Free download

China-Related Transactions Export-Control Screening Sheet (fill-in / Export Control Law & Dual-Use Regulations, critical minerals, Control List, 2026)

A fill-in working sheet for companies trading with China: screen a single transaction against China's export-control regime (the Export Control Law and the Dual-Use Items Export Control Regulations), the controls on critical minerals (gallium/germanium/graphite/antimony/tungsten etc./rare earths/helium), and the four counterparty-list systems (Control List, Watch List, Unreliable Entity List, countermeasure lists). A procedure for "what to check before the deal," not a roster of "who is listed." With a plain-language intro, based on MOFCOM announcements. Listing is a regulatory category, not a judgment about any company (including the Japanese firms on the Japan-directed lists); controls change continually, so verify current announcements and consult your officer. Match counterparties using the original simplified-Chinese wording.

Download for free

Related Knowledge Base

Enterprise AI Guide

Solutions

Solve Knowledge Management ChallengesCentralize internal information and quickly access the knowledge you need

Learn More About AIコンサル

Discover the features and case studies for AIコンサル.

Contact UsView AIコンサル Details

Related Articles

CES Roundup: Scope3 at CES 2025 and the Best Products from CES 2024

CES Roundup: Scope3 at CES 2025 and the Best Products from CES 2024

A practical guide to CES Roundup: Scope3 at CES 2025 and the Best Products from CES 2024. Topics include Business, Consulting, AI.

2026-02-07
Will AI Reshape the Web? Netlify Co-Founder Matt Biilmann on the Coming Agent Experience Era

Will AI Reshape the Web? Netlify Co-Founder Matt Biilmann on the Coming Agent Experience Era

A practical guide to Will AI Reshape the Web? Netlify Co-Founder Matt Biilmann on the Coming Agent Experience Era. Topics include Business, Consulting, AI.

2026-01-21
OnePlus 13S: The Compact Flagship That Proves Small Doesn't Mean Compromise

OnePlus 13S: The Compact Flagship That Proves Small Doesn't Mean Compromise

The smartphone market has trended relentlessly toward larger screens. For a period, "compact flagship" meant accepting hardware compromises.

2026-01-21
Full-Body Training at Home: The Compact Speediance Gym Monster 2 Home Gym

Full-Body Training at Home: The Compact Speediance Gym Monster 2 Home Gym

A practical guide to Full-Body Training at Home: The Compact Speediance Gym Monster 2 Home Gym. Topics include Business, Consulting, AI.

2026-01-21
Generate:Biomedicines — How AI-Driven Drug Discovery Is Cutting Development Time and Improving Capital Efficiency

Generate:Biomedicines — How AI-Driven Drug Discovery Is Cutting Development Time and Improving Capital Efficiency

The average drug development timeline is 13 years. Average cost per approved drug: several billion dollars.

2026-02-07
Genspark Complete Guide: Research, Image Generation, Video Generation, Deep Research, and What to Watch Out For

Genspark Complete Guide: Research, Image Generation, Video Generation, Deep Research, and What to Watch Out For

Genspark Complete Guide: Research, Image Generation, Video Generation, Deep Research, and What to Watch Out For.

2026-02-07